New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
08:37 EDTSHPGShire price target raised to $205 from $182 at Susquehanna
Susquehanna raised its price target on Shire following increase company guidance. The firm believes guidance remains conservative citing its growth, balance sheet, and its potential to attract a premium bid. Shares are Positive rated.
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
08:52 EDTSHPGShire deserves premium valuation, says Susquehanna
Susquehanna said Shire deserves its premium valuation as it continues to deliver solid performance from marketed products while investing for longer-term growth from its pipeline. Susquehanna reiterated its Positive rating and $290 price target on Shire shares.
07:26 EDTSHPGWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
07:02 EDTSHPGShire and the Foundation Fighting Blindness announce agreement
Shire and the Foundation Fighting Blindness announced a new agreement focused on furthering research for a novel treatment for autosomal dominant retinitis pigmentosa, or adRP, a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There are no currently approved treatment options for adRP. As part of the agreement, the Foundation Fighting Blindness and its research partners will provide Shire with expert knowledge and scientific background regarding adRP, as well as pertinent clinical information that could be useful in the development of a drug to treat adRP. Shire is compensating the Foundation Fighting Blindness for its considerable expertise in early-stage drug discovery and development, as well as making available it significant expertise and experience with the submission of investigational new drug applications.
May 1, 2015
12:26 EDTSHPGBiogen patent challenged by Kyle Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1-20 of US patent 8,399,514 held by Biogen (BIIB), according to a USPTO filing. The patent is related to the company's multiple sclerosis drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Celgene (CELG), Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). PRICE ACTION: Shares of Biogen are up 3% to $385.29 in afternoon trading.
10:20 EDTSHPGShire management to meet with Jefferies
Subscribe for More Information
08:44 EDTSHPGShire price target raised to $298 from $262 at SunTrust
Subscribe for More Information
April 30, 2015
07:09 EDTSHPGShire reaffirms 2015 EPS growth outlook of mid-single digits
Shire said, "We've made a strong start to 2015, and remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015. On a Constant Exchange Rate basis we continue to expect product sales growth in the mid-to-high single digits. When excluding INTUNIV, we anticipate low double digit product sales growth on a CER basis. Based on current exchange rates we anticipate low-to-mid single digit product sales growth in 2015, as we expect growth to be held back three to four percentage points by foreign exchange headwinds which particularly impact ELAPRASE, REPLAGAL and VPRIV sales. We expect to see a lower rate of product sales growth through the remainder of 2015 than we've delivered in the first quarter, principally due to stronger comparatives. Royalties and other revenues are expected to increase by 30-40% in 2015, as we include NPS's royalty streams for the first time. Our Non GAAP gross margin is expected to be in line with 2014."
07:08 EDTSHPGShire reports Q1 adjysted EPS $2.84, consensus $2.61
Subscribe for More Information
07:06 EDTSHPGShire appoints Jeff Poulton as CFO
Subscribe for More Information
April 29, 2015
10:00 EDTSHPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:33 EDTSHPGShire initiated with an Outperform at Exane BNP Paribas
Subscribe for More Information
April 23, 2015
09:20 EDTSHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
07:07 EDTSHPGEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 20, 2015
14:32 EDTSHPGPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use